Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring ...

These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...

The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Kyverna Therapeutics, Inc. (($KYTX)) announced an update on their ongoing clinical study. Kyverna Therapeutics, Inc. is conducting a clinical ...

The use of existing guidelines for pediatric treatment varies significantly among sites, a new study has found. The study findingssuggest wide variation exists in the medications prescribed to treat ...

WASHINGTON, DC — A novel antibody, obinutuzumab (Genentech-Roche), enhances renal responses in patients with lupus nephritis, through more complete B-cell depletion, compared with standard ...

DelveInsight's Lupus Nephritis Market Insights report includes a comprehensive understanding of current treatment practices, lupus nephritis emerging drugs, market share of individual therapies, and ...